

CheckmAb's Immunotherapy in Collaboration with Boehringer Ingelheim Advances to Next Stage



From left to right: the scientists [Mirco Toccafondi](#) , [Noemi Di Marzo, PhD](#) , [Elena Zagato](#) . The Board of Directors: Sergio Abrignani (Founder), [Giorgio Barba Navaretti](#) , [Renata Grifantini](#) (Chief Scientific Officer and General Manager), [Massimiliano Pagani](#) (Founder), [Marco Venturelli](#) (President of the Board), [Carlo Marchetti](#) . The scientists [Luca Sorrentino](#) ([Donatella Maria Balconi](#) and [Simona Siciliani](#) Secretariat and Legal Office representative), the scientists [Cecilia Valvo](#) and [Federica Bianchi](#).

Milan, Italy, February 4th 2025 – CheckmAb S.r.l. announced today the successful achievement of the second milestone in the collaboration with Boehringer Ingelheim for the development of a monoclonal antibody (mAb) for cancer immunotherapy.

Cancer immunotherapies have delivered meaningful therapeutic options to some cancer patients, yet many patients still do not respond to such therapies. The antibody under the licensing agreement selectively targets tumor-infiltrating regulatory T lymphocytes (TI-Tregs) without affecting other immune cells outside of the tumor. It offers the potential to overcome some of the limitations of current immune-checkpoint inhibitors and potentially improve patient outcomes by activating anti-tumor immune responses without disrupting other functions of the immune system.

The ongoing collaboration and development of this antibody underscores Boehringer Ingelheim's commitment to extend the benefits of immunotherapy to cancer patients still in need for better medicines.

“Reaching this milestone is a fantastic achievement and highlights the significant progress made by the teams. This would not be possible without the excellent collaboration and working relationship that continues to build between Boehringer Ingelheim and CheckmAb,” said Renata Maria Grifantini, Chief Scientific Officer of CheckmAb. *“We look forward to continuing to work with Boehringer as they take this program forward with the ultimate goal of developing safe and effective therapies for multiple tumor indications across patient populations.”*

Under the terms of the license agreement, CheckmAb will receive a milestone payment from Boehringer Ingelheim. CheckmAb is eligible for additional research, development and commercial milestones up to EUR 240 million as well as royalties on the potential sales of any therapeutics arising from the collaboration and licenses.

This announcement follows the extension of the research collaboration under the licensing agreement announced in March 2023.

###

CheckmAb

CheckmAb Srl is a preclinical-stage biotechnology company based in Milan, Italy discovering and developing therapeutic candidates for cancer and autoimmune diseases based on proprietary knowledge of selected targets. At present, CheckmAb is developing mAbs against lead targets able to selectively deplete tumor-infiltrating Treg cells and to reactivate effector T cell lymphocytes to destroy tumor cells.

The CheckmAb technology is based on the unique insights and expertise of its founders, scientists and shareholders Massimiliano Pagani and Sergio Abrignani and derives from the translational research approach developed at INGM, the Istituto Nazionale di Genetica Molecolare “Romeo ed Enrica Invernizzi” and at the University of Milan, both current shareholders.

The main financial partner of CheckMab is Fondo Health, an investment fund, that was launched and sponsored by ENPAM, the first pillar private pension scheme of medical doctors and dentists, with the aim to promote Italian health care excellence. Fondo Health is managed by Primo Capital SGR, a leading Italian AIFM specialized in vertical technology investments.

For more information, please visit please visit www.Checkmab.eu

Media contact:

Dr. Renata Maria Grifantini

CheckmAb S.r.l.

Via Francesco Sforza, 35 - 20122 Milano

Tel. +39 02 0066 0201

email: renata.grifantini@checkmab.eu